FCB Health is looking to humanize data, formalizing that vision into its own distinct next generation big data agency named Solve(d).
J&J could suffer a big patent loss for Zytiga, but even if that happens, the company argues it can grow faster than its peers.
Strong data for Dupixent in sinusitis could boost sales for Sanofi and Regeneron, but challenges abound, including payer pushback.
EU regulators say they have found the same impurity discovered in valsartan in both losartan and irbesartan.
The punishment, an amount rarely seen in China, includes confiscation of illegal gains and a fine three times those sales.
For the third year in a row, the percentage of U.S. kindergarteners with a vaccine exemption has grown, this time to 2.2%.
Pharma might have thought it could fend off the Trump administration's bid to get drug prices into consumer advertising, but it was wrong.
As Sanofi mobilizes millions of flu shots, it's working with the American Lung Association to make sure vaccines get to the people who need them.…
Genzyme is reportedly looking for 400,000 square feet of space near its headquarters, hoping to gather scattered operations and secure room to grow.
After a CMS rule change in August, UnitedHealthcare is introducing step therapy in Medicare Advantage plans to favor biosimilars over certain brands.